News from 3CTN                                                     View this in your browser
Montreal Children’s Hospital open house welcomes patients and highlights cancer research
To mark childhood cancer awareness month in September, the research team at Montreal Children’s Hospital’s (MCH) held an open house showcasing pediatric cancer research projects and their impact on survival for cancer patients.

The event commenced with a networking reception with more than 75 people in attendance ranging from hospital staff to families of children with cancer. The first speaker, a pediatric patient, talked about her experience of participating in a clinical trial and the importance of cancer research.

Research staff, Stephanie Badour and Emma Anillo, shared news on the hospital’s cancer research activities and recent accomplishments. Educational presentations included information on clinical trials phases, the importance of research in relation to outcomes and the spectrum of unique pediatric cancer trials currently offered at MCH. Physician staff members spoke about ongoing research in oncogenomics and personalized medicine. An engaging question-and-answer session provided attendees an opportunity to discuss topics further.

Upon conclusion, Badour shared her thoughts, “The open house showcased the hope that oncology research provides for pediatric cancer patients. Our research team is looking forward to hosting again next year.”
Year 6, Quarter 1 recruitment to academic cancer clinical trials
This figure shows the breakdown of accruals by province as well as adult & pediatric populations. As of the end of Q1, 3CTN Cancer Centres were collectively on track towards meeting the annual target of 60 percent above baseline recruitment.
Introducing 3CTN’s Patient Representative Community
of Practice
Over the past year, Network centres have been incorporating patients as contributing members of their clinical trials unit. Progress is ongoing with about half having identified and on-boarded Patient Representatives.

As new Representatives are added, creating a support structure is key to help orient clinical staff and patient members to their roles in establishing an effective and sustainable community of patient advisors in research activities.

Beyond developing the initial on-boarding tools in the Patient Representative Orientation Toolkit, the Network has a unique opportunity to support individual site clinical research staff and patients in the delivery of clinical research training, ongoing education and peer support. Moreover, Canada’s diverse geography emphasizes the need to bring Patient Representatives together. Thus, the Patient Representative Community of Practice (PRCoP) was formed, a one-of-a-kind community of patient advisors to further clinical trials conduct in Canada.

Looking ahead, the Network will adhere to established patient engagement quality criteria to identify and implement appropriate learning modules covering aspects of research and clinical trials design. The PRCoP will be integral in guiding 3CTN’s continued patient and public involvement strategy and local site activities. 
Q-CROC launches its new search engine for oncology clinical trials - OncoQuebec
OncoQuebec is a web-based application to search for clinical trials in oncology in Quebec and was launched by Quebec Clinical Research Organization in Cancer. It is an intuitive search system that meets the needs of providers, patients and their loved ones.
Search for trials
Writing good lay summaries for your clinical trials
Do you need help with writing good lay summaries and lay documents? The Coordinating Centre has compiled guiding documents.
See links under Tools
ASCO Eligibility Guidelines – Broadening Access to Clinical Trials
3CTN supports the move towards more inclusive clinical trial eligibility criteria for potential patients. The American Society of Clinical Oncology (ASCO) and Friends of Cancer Research began a joint project in 2016 to develop and advance specific strategies to change the exclusionary nature of study eligibility criteria. A joint research statement and four supporting manuscripts on the topic were published in the Journal of Clinical Oncology in October 2017. Five guidance documents on ways to broaden protocol eligibility criteria for cancer clinical trials were submitted to the FDA on August 8, 2018.
Read ASCO recommendations
Special announcements
3CTN Annual Report 2018/19
Supporting the conduct of and demonstrating the impact of academic cancer clinical trials to yield better outcomes for Canadian cancer patients is at the heart of the work we do. This report summarizes key accomplishments over the last year. 
Read the report
Remote patient access to clinical trials workshop
3CTN is spearheading an initiative that seeks to improve access to clinical trials for patients where distance to a cancer centre currently poses a barrier to participation. A Steering Committee of experts was established to guide this initiative and a workshop comprising of the clinical research community and patient stakeholders will be held at the 2019 Canadian Cancer Research Conference in Ottawa on November 5. Workshop outcomes will be used to develop a framework that addresses regulatory, ethical, legal and practical requirements for implementation in Canada.
Key dates ahead
November 5: Remote Patient Access Workshop 
November 12: Recruitment/PPI Workshop
November 13: Annual Stakeholder Meeting
November 15: Reports due for Year 6, Quarter 2
November 2019:  Scientific Advisory Board, 18-month review - Network status report development
Do you have news to share?
Be featured in the next issue of 3CTN's Network Pulse by submitting a brief (~200 word) story along with pictures to
Copyright © 2019 Canadian Cancer Clinical Trials Network, All rights reserved.
You are receiving this email because you are signed up to receive 3CTN's Quarterly Newsletter or because you are affiliated with the Network.

Our mailing address is:
Canadian Cancer Clinical Trials Network
MaRS Centre
661 University Ave, Suite 510
Ontario, Canada 
M5G 0A3
Follow us: @3ctnNews

This email was sent to <<Email Address>>
why did I get this?    unsubscribe from this list    update subscription preferences
Canadian Cancer Clinical Trials Network · 661 University Ave · Suite 501 · Toronto, On M5G0A3 · Canada

Email Marketing Powered by Mailchimp